Arthneeti
Fundraise / allotmentMajor developmentFiled on BSE ·

Viyash Scientific Q1 results, ESOP allotment, Vietnam subsidiary and AAHL rights issue

Viyash Scientific · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read
₹79.3 CrFundraise / allotment

Key highlights

  • Board approved unaudited standalone and consolidated results for the quarter ended June 30, 2026; auditors issued limited review reports. Consolidated profit after tax was Rs. 792.90 million versus Rs. 368.50 million (restated) a year earlier.
  • Board approved allotment of 10,30,775 equity shares at Rs. 101 each under ESOP Scheme 2026; capital will rise to Rs. 87,98,15,176 after the proposed allotment.
  • Board approved subscription to AAHL rights issue of up to Rs. 400,02,15,648, set off against intercompany loan; approved incorporation of a Vietnam step-down subsidiary.

Why it's rated major development: the year-on-year change is 115% (50% or more)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Board Meeting Outcome for Outcome Of Board Meeting

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Viyash Scientific

Other fundraise / allotment filings this fortnight

All fundraise / allotment filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.